OrbiMed’s Altimmune ALT Stock Holding History

OrbiMed’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-100,000	Closed	-$260K	–	113
2023 Q3	$260K	Hold	100,000	–	–	0.01%	125
2023 Q2	$353K	Buy	100,000 +49,400	+98%	+$222K	0.01%	125
2023 Q1	$214K	Buy	+50,600	New	+$601K	﹤0.01%	124

Other funds holding ALT

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TIM

Timelo Investment Management Aurora, Ontario, Canada $127M AUM 23.73% 1-Year Est. Return

OrbiMed's ALT Position: Q4 2023 in Review

OrbiMed sold out of Altimmune (ALT) in Q4 2023, closing a stake of 100,000 shares — an estimated $260K sold.

OrbiMed first reported a position in ALT in Q1 2023 and held it in 3 quarters. The position peaked at $353K in Q2 2023. 143 funds tracked by Wall St. Rank hold ALT as of Q4 2023.

OrbiMed reported no remaining Altimmune position as of Q4 2023 after selling out during the quarter.
OrbiMed sold 100,000 Altimmune shares in Q4 2023, an estimated $260K.
OrbiMed first reported a position in Altimmune in Q1 2023 and held it in 3 quarters.
OrbiMed's Altimmune position peaked at $353K in Q2 2023.
143 funds tracked by Wall St. Rank held Altimmune as of Q4 2023.

Based on OrbiMed's 13F filing for Q4 2023, filed 14 Feb 2024.